Abstract Number: 0525 • ACR Convergence 2023
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…Abstract Number: 1349 • ACR Convergence 2023
Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…Abstract Number: 1405 • ACR Convergence 2023
Diagnostic Delay of Axial Spondyloarthritis in African American Patients
Background/Purpose: The identification of axial spondyloarthritis (axSpA) remains challenging. The initial presentation is not always immediately apparent as an inflammatory disease, potentially leading to years…Abstract Number: 1892 • ACR Convergence 2023
Sacroiliac Bone Marrow Oedema on Postpartum MRI Does Not Result in Significant SpA-like Structural Lesions: Results of a 5-year Follow-up Study
Background/Purpose: Sacroiliac bone marrow oedema (BMO) on MRI, immediately after childbirth, has been observed in a large proportion of postpartum women and appears to be…Abstract Number: 0526 • ACR Convergence 2023
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…Abstract Number: 1383 • ACR Convergence 2023
Long-term Association Between Physical Activity and Global Functioning in Patients with axSpA: Results of a 2 Year Prospective Study
Background/Purpose: To assess the longitudinal association between physical activity and global functioning in patients with axial spondyloarthritis (axSpA) and to identify the subtype of physical…Abstract Number: 1406 • ACR Convergence 2023
Temporal Trends in Cardiovascular Events in Axial Spondyloarthritis Patients with Medicare Insurance versus Commercial Insurance: An Analysis Using Claims Data
Background/Purpose: AS is an inflammatory disorder of the axial skeleton and can cause complications including disabling joint damage. Nearly 20% of people with AS are…Abstract Number: 2164 • ACR Convergence 2023
Real-world Persistence of Initial Targeted Therapy Strategy in Monotherapy versus Combination Therapy in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Background/Purpose: Clinical practice guidelines, based on information from clinical trials, provide different recommendations for the use of combination therapies for the treatment of rheumatoid arthritis…Abstract Number: 0528 • ACR Convergence 2023
Risk of Cardiovascular Disease Associated with Long-term Use of NSAIDs in Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is associated with increased cardiovascular disease, but there are limited data as to whether prolonged treatment with non-steroidal anti-inflammatory drugs (NSAIDs)…Abstract Number: 1384 • ACR Convergence 2023
Functional Status by Sex and Socioeconomic Status in Axial Spondyloarthritis
Background/Purpose: Women with axial spondyloarthritis (axSpA) tend to have worse patient reported outcomes compared to men. Non-U.S. studies have evaluated functional status (FS) by sex…Abstract Number: 1407 • ACR Convergence 2023
Defining Thresholds of Presenteeism Measures for Unacceptable Work Participation in axSpA
Background/Purpose: Presenteeism is associated with lower work satisfaction and future sick leave in axial spondyloarthritis (axSpA). It is generally assessed as a continuous variable; however,…Abstract Number: 2213 • ACR Convergence 2023
Identification of a Diagnostic Model for Axial Spondyloarthritis in Daily Clinical Practice Using a Random Forest Machine Learning Approach
Background/Purpose: In axial spondyloarthritis (axSpA), early diagnosis plays a key role in preventing disease progression. However, a validated diagnostic algorithm does not exist, while classification…Abstract Number: 0090 • ACR Convergence 2023
Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory disease that predominantly affects the spine and the sacroiliac joints. Dysregulation of Type 3 immunity has been implicated…Abstract Number: 0531 • ACR Convergence 2023
Effects of Anti-tumor Necrosis Factor Treatment on Lipid Profiles in Patients with Ankylosing Spondylitis
Background/Purpose: To investigate the effects of anti-tumor necrosis factor (anti-TNF) treatment on lipid profiles and identify risk factors for elevated total cholesterol (TC) after the…Abstract Number: 1385 • ACR Convergence 2023
Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers
Background/Purpose: Several sets of treatment recommendations for axial spondyloarthritis and ankylosing spondylitis (axSpA/AS) have been published. Clinical practice guidelines are not followed consistently by health…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 62
- Next Page »